drugset / Trial / NCT04088318

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

NCT04088318 ↗

Phase 2 Unknown 170 enrolled OnQuality Pharmaceuticals (USA) LLC
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.

Timeline

Start
2019-12-09
Primary completion
2024-02-26
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject OQL011 Unknown — Topical

Indications